Effect of two prophylactic bolus vitamin D dosing regimens (/day vs. /day) on bone mineral content in new-onset and infrequently-relapsing nephrotic syndrome: a randomised clinical trial.

What Was Tested

This randomized controlled trial looks at Vitamin D, K2, Magnesium and Zinc.

Who Took Part

According to the abstract, 92 children were involved.

By PubMed's age tags, the people studied were infants, young children, children and teenagers, both men and women.

The proportionate change in bone mineral content (BMC) was analysed in both groups after vitamin D supplementation.

How the Study Was Run

In design terms this was a randomized, open-label and parallel-group study.

The children were allocated by chance, so the Vitamin D, K2, Magnesium and Zinc group and the comparison group should start out alike.

Everyone knew when Vitamin D, K2, Magnesium and Zinc was being given (open label), which is simpler to run but leaves more room for expectations to affect what is reported.

The Vitamin D, K2, Magnesium and Zinc group and the comparison group ran side by side rather than switching.

What Was Measured

Topics PubMed links to this paper include Adrenal Cortex Hormones, Bone Density, Chemoprevention, Nephrotic Syndrome, Osteoporosis and Vitamin D.

The authors tagged it with the keywords BMC, bone mineral content, BMD, bone mineral density, DXA, dual energy X-ray absorptiometry, IFRNS, infrequently relapsing nephrotic syndrome, NS, nephrotic syndrome and calcium.

What This Means in Plain Language

The paper is a randomized, open-label and parallel-group study of Vitamin D, K2, Magnesium and Zinc in 92 children.

Its findings take up roughly 10 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2018 (Paediatrics and international child health), a journal based in England.

More context: the Vitamin D, K2, Magnesium and Zinc compound page, all human trials.